TW200800292A - Accelerating agent of calcium absorption - Google Patents
Accelerating agent of calcium absorption Download PDFInfo
- Publication number
- TW200800292A TW200800292A TW096105942A TW96105942A TW200800292A TW 200800292 A TW200800292 A TW 200800292A TW 096105942 A TW096105942 A TW 096105942A TW 96105942 A TW96105942 A TW 96105942A TW 200800292 A TW200800292 A TW 200800292A
- Authority
- TW
- Taiwan
- Prior art keywords
- calcium
- accelerator
- disease
- treatment
- manufacture
- Prior art date
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 65
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 54
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 11
- 238000010521 absorption reaction Methods 0.000 title abstract description 22
- 229920000084 Gum arabic Polymers 0.000 claims abstract description 42
- 239000000205 acacia gum Substances 0.000 claims abstract description 42
- 235000010489 acacia gum Nutrition 0.000 claims abstract description 42
- 241000978776 Senegalia senegal Species 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 12
- 210000000988 bone and bone Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 239000003655 absorption accelerator Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims 5
- 210000003802 sputum Anatomy 0.000 claims 5
- 208000024794 sputum Diseases 0.000 claims 5
- 206010020565 Hyperaemia Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 230000003610 anti-gingivitis Effects 0.000 claims 1
- 235000021375 calcium rich food Nutrition 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 238000005336 cracking Methods 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 208000020854 vein disease Diseases 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
- 235000013325 dietary fiber Nutrition 0.000 abstract description 6
- 229960005069 calcium Drugs 0.000 description 43
- 244000215068 Acacia senegal Species 0.000 description 39
- 230000000694 effects Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 206010006956 Calcium deficiency Diseases 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 8
- 208000006386 Bone Resorption Diseases 0.000 description 6
- 230000024279 bone resorption Effects 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 208000005368 osteomalacia Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000024668 brittle bone disease Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- QXKAIJAYHKCRRA-JJYYJPOSSA-N D-arabinonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(O)=O QXKAIJAYHKCRRA-JJYYJPOSSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- PMNYTGAGAKEGJE-UHFFFAOYSA-N ethane-1,2-diamine;sodium Chemical compound [Na].[Na].NCCN PMNYTGAGAKEGJE-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000021189 garnishes Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- -1 shell powder Natural products 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Botany (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
Description
200800292 九、發明說明: 【發明所屬之技術領域】 本發明係關於一種促進鈣吸收之試劑。 【先前技術】 人體内鈣水平係藉由分別平衡胃腸道吸收與排泄及腎小 管再吸收與排泄而保持恆定。因此,缺鈣係慢性腎衰竭症 狀之一。另外,缺鈣很常見,此乃因不容易發現包含大量 妈的各種食物,且在許多情況下吸收效能不夠。缺鈣會造 成脆骨症且可引起骨質疏鬆症及骨軟化,且因此吾人希望 找到一種提高小腸鈣吸收及/或鈣之骨吸收之效能的方 法。 由於保持平衡血鈣對良好的心臟功能至關重要,因此缺 鈣亦與心血管疾病有關,例如動脈粥樣硬化、冠狀動脈疾 病、局部缺血性心臟病、高血脂症及高血壓。吾人亦已發 現約能降低膽固醇水平。 、可又凰於#5吸收提鬲之其他病況係瘧疾、潰瘍性結腸 炎、齒齦炎或齒斑,及學習缺陷,例如阿茲海默氏症 (Alzheimer’s)或老年性癡呆症。 GA(阿拉伯樹膠)係一種得自阿拉伯膠樹 gal)(丑科植物類)或其他阿拉伯種類(豆科植物類)之主 幹及或刀枝的膠黏性分泌物。ga主要組份係阿拉伯酸(79 。)其以Ca、Mg及/或κ鹽形式存在。ga酸解產生L- 阿拉伯糖、K丰a μ τ ^ ^ 卞孔糖、L-鼠李糖及D·葡萄糖醛酸。此外, 中存在痕里水解酶及氧化酶,連同少量礦物質及蛋白 I18664.doc 200800292 質。 .、/、/埃及時代起’便已將GA用作治療牙周病及牙槽膿 溢(治療齒報出血、消除齒齦潰瘍’或促進牙齒生長)、肺 病及肝病之民間藥物。 、田刖,G A作為乳化劑與調味劑一起用來保持果汁及冰 溪淋成份之均一性,作為食物添加劑用來保持糖果之形狀 且作為藥物穩定劑用來壓製鍵劑或防止液體調配物中成份 ^ 之歧化。 GA係一種膳食纖維,其難以由消化酵素消化,且一般 已知會阻止胃腸道鈣吸收。丁〇kky〇 K〇kai H〇9_67257(i997) 揭不藉由降低曱殼質分子量而給予其以促進礦物質吸收作 用之旨试,此乃因大分子量甲殼質會阻止礦物質吸收,例 如舞、鎭及諸如此類。人們亦提出一種藉由將乳糖及糖_ 酉予添加至膳食纖維中而改良鈣吸收之方法(T〇kky〇 2002-142721) 〇 • 對於GA,揭不其對小腸水及鈉離子之吸收具有加速作 用,但尚未報導其對小腸鈣吸收或骨吸收具有加速作用。 【發明内容】 人們認為膳食纖維係最重要營養素之一,此乃因其藉由 控制胃腸道葡萄糖攝取速率而防止進餐後血糖快速升高, 並避免便秘及由便秘帶來的有害物質在腸道中的排放。 本發明提供一種鈣吸收加速劑,其視情況可與膳食纖維 一起每天服用以避免缺鈣。本發明者出乎意料地發現GA 對胃腸道鈣吸收具有加速作用。 I18664.doc 200800292 根據本發㈣,提供—種包 收加逮劑。 拉伯樹膠之鈣吸 據本發明第二態樣,提供—種包㈣試劑及如 義加速劑之富飼食物。 疋 :據=明第三態樣’提供一種如上所定義 ®鈣食物t之用途。 牡
劑根:= 第四態樣’組合物包括阿拉伯樹膠及約試 、且°扇來在治療中同時、分開或依序使用。 :據本發明第五態樣’提供阿拉伯樹膠在製造用來治療 5 1防與缺㉝有關之疾病之藥物中的用途。 、止根據本發明第六態樣’提供如上所定義之加速劑用來製 、用於/口療或預防慢性腎衰竭或與慢性腎衰竭有關之缺鈣 之藥物的用途。 根據本發明第七態樣’提供如上所定義之加速劑在製造 用於治療或預防包括動脈粥樣硬化、冠狀動脈疾病、局部 缺血n病、尚血脂症及高血壓之一種或多種在内之心 血官疾病之藥物中的用途。 根據本發明第八《,提供如上所定義之加it劑在製造 用於/口療或降低高膽固醇血症患者中膽固醇之藥物中的用 途。 根據本赉明弟九怨樣,提供如上所定義之加速劑在製造 用於治療或預防瘧疾之藥物中的用途。 根據本發明第十態樣,提供如上所定義之加速劑在製造 用於治療或預防潰瘍性結腸炎之藥物中的用途。 118664.doc 200800292 根據本發明第十一態樣,提供如上所定義之加速劑在製 造用於治療或預防齒齦炎或齒斑之藥物中的用途。 根據本發明第十二態樣,提供如上所定義之加速劑在製 造用於治療或預防學習缺陷(例如阿兹海默氏症或老年性 癡呆症)之藥物中的用途。 缺鈣可造成脆骨症且可引起骨質疏鬆症及骨軟化。本發 明可提高小腸鈣吸收及/或鈣之骨吸收效能並預防上述疾 病,且同時攝入係重要營養素之一之膳食纖維。因此,本 發明亦係用來製造治療或預防骨質疏鬆症及/或骨軟化之 藥物的阿拉伯樹膠。該藥物亦可包括鈣補充劑/試劑。 【實施方式】 作為本發明中之可溶於水的樹膠,源自諸如阿拉伯膠樹 及阿拉伯相思樹(Acacia seyai)之阿拉伯種類(豆科植物類) 之主幹及/或分枝的膠黏性分泌物可以其原樣使用。出於 易獲取及易調配之觀點,該樹膠及/或該樹膠之提取物之 乾燥粉末較佳。 較佳之提取溶劑係水。含水提取物可直接使用或在濃 縮、稀釋及/或純化後使用。 乾燥粉末及/或提取物可借助於管柱層析進行純化。 本發明加速劑可藉由使其與含鈣食物(舉例而言,乳製 品,例如牛奶、酸奶、乾酪及諸如此類)混合,且在缺鈣 或不含約食物情況下藉由添加詞試劑而加以制。該情況 下所使用鈣試劑包括(但不限於)食物添加劑,包括鈣鹽, 例如碳酸鈣、乳酸鈣、葡萄糖酸鈣、乙酸鈣、檸檬酸鈣、 I I8664.doc 200800292 “鈣、氯化鈣及氫氧化鈣;及天然產品,例如殼粉、珊 瑚粉、蛋殼、牛奶、牛骨粉。 為補饭鈣缺乏,本發明加速劑可藉由使其與各種食物及 叙料(田約食物)混合以及藉由使其與上述妈試劑結合而加 以使用。富詞食物包括(但不限於)碳酸飲料、果汁、發酵 飲料、牛奶飲料例如牛奶;冷床甜食,例如冰淇淋、冰牛 奶,礼衣〇口,例如酸奶、乾酪;午餐肉,例如火腿、香 • 腸;魚醬製品;麵包熱糕點、精製食品、奶油焦糖、湯及 諸如此類。 若需要,可向該飲料調配物中添加適宜量的甜味劑,例 如糖蜂雈、甘油及天冬甜素;調味品,例如大蒜及墓; 香料例如果味劑,抗氧化劑,例如乙二胺二納鹽及硫代 硫酸鈉;胺基酸,例如白胺酸、甲硫胺酸、離胺酸及牛磺 酸;及維他纟’例如維他命A、$他命B、維他命C、維他 命D、維他命E及煙醯胺。 • » 2可向該口服飲料調配物中添加天然果汁(例如橙汁、 葡萄柚汁及蔬菜汁(羽衣甘藍嫩葉或大麥)及/或原生藥⑼ 如人苓及幼鹿鹿茸)提取物。 本發明加速劑亦可用於除人類以外的動物,且可用作寵 物食物’例如狗食或貓食及動物飼料。 如上所述’本發明加速劑可單獨或與其他食物或飲料一 起口服。待服用試劑之量取決於每種食物或飲料之配方; 及服用該試劑者之性別 '年齡及體重,但通常為 克/天、較佳10至50克/天、且更佳難2G克/天。當該試劑 118664.doc 200800292 溶解或懸浮於冷水、熱水或醇中後,盆 八f T便具可納入各種調配物 中 〇 實例 GA對腸道鈣吸收之影響係根據下列方法分析。 在每一測試中,皆使用得自SANKY〇 F〇〇ds ind⑽try公 司之純化GA及L-乳酸鈣(Sigma),已習知後者具有高溶解 度(9600 ¾克/100克H2〇)且對食物味道沒有影響。將重量 200至250克、及尤其在研究鈣骨吸收實驗(測試實例3)中約 12〇克之雄性Wistar大鼠用作實驗動物。 測試實例1 -藉助灌注法小腸吸收效能之研究(於原位) 1. 方法 切開用戊巴比妥(pentobarbital)(5〇毫克/毫升/公斤,腹 膜内)麻醉之大鼠的腹腔並將矽管插入十二指腸及闌尾 中。使包含#5(1¾克/毫升)或約與GA(7,5%)之灌注溶液流 動穿過腸道,隨時間記錄灌注溶液並分析舞含量。 2. 結果 結果示於圖1中。其表明GA增加小腸妈吸收之效能。 測試實例2 -對尿液排泄之影響 通常,血液中鈣濃度係藉由生物體内平衡而保持恆定但 將其用作鈣吸收指數較為困難。因此,對鈣的尿液排泄實 施分析來替代之。 1.方法 使大鼠飼養在代謝籠中並給予包含鈣(Ca)、阿拉伯樹膠 (GA)或Ca與GA (Ca+GA)之40毫升水並持續3天。另外,給 118664.doc 200800292 其薇食缺鮮飲食以消除正常飲食中所包含舞的影響。回收 尿後’量測尿液的鈣濃度及尿液體積。 2 ·結果 結果示於圖2中。使用代謝籠回收尿且持續3天並分析詞 的尿液排泄。在經療組中,㈣尿液排泌量未 增加’而在經(Ca+GA)治療組中尿液排;世量明顯增加。因 此,亦表明活體内攝取GA增加舞吸收之效能。 測試實例3對妈之骨吸收之影響 接著,藉助餵食缺鈣飲食之大鼠研究GA對鈣吸收之加 速作用是否觸及骨吸收,並防止骨中鈣含量下降。 1. 方法 以1毫克(ca)/天之量將鈣(經Ca治療組)、或鈣與GA(經 [Ca+GA]治療組)經口投與大鼠並持續3〇天,並觀察股骨之 硬度及礦物質(Ca、Mg、p、Zn)含量之變化或血液中 ALP。給大鼠餵食缺鈣飲食以消除正常飲食中所包含鈣的 影響。 2. 結果 結果示於圖3至6中。 才又與30天後,當體重與開始時體重相比時,經[Ca+GA] 治療組表現出體重增加(圖3)。開始投與3〇天後,所量測之 股骨硬度證實與經Ca治療組或對照組相比,經[Ca+GA]治 療組之骨中硬度表現出增加趨勢。 此外’量測骨中各種礦物質即Ca、Zn、MgAp之含量, 且Ί [CA+GA]治療組之骨中Ca、Mg&p含量之下降明顯降 118664.doc 12 200800292 低。鹼性磷酸酶(ALP)係一種加速鈣之骨吸收之酵素且已 白知§骨中鈣含量降低時其在血液中有所增加,並且在該 貝驗中亦觀察到經Ca治療組中血液中ALp升高。然而,與 、、二Ca治療組相比,共投與GA表現出降低alp升高之趨 勢。 忒等貫驗結果表明Ca與GA共投與提高了小腸鈣吸收之 效旎,且長期投與降低了骨中鈣含量之下降。因此,吾人 已提出GA用於骨吸收加速劑之新穎用途。 飲料試劑之製備 使ga(io克)分散於溫水(4(rc,3〇毫升)中並加以攪拌。 冷卻混合物至25。(:後,添加維他命B](1〇毫克)、維他命 Β6(ιο毫克)、咖啡因(5〇毫克)、糖(5克)、蜂蜜(5克)、擰檬 酸(400毫克)、擰檬酸納(50毫克)及苯甲酸納(35毫克)並加 以授拌。#由添加乳酸及/或(Μ N氫氧化鈉將所得混合物 之PH值調節至6.〇。隨後藉由添加水將該所得溶液之總體 積調節至5毫升。 該實例中所使用之GA如下進行…將得自蘇丹 (Sudan)阿拉伯膠樹之〇人粉化並溶於水中。隨後過濾所 溶液並喷霧乾燥濾液以得到該GA。 心 工業應用性 由本發明提供之㈣收加速劑可(例如)藉由與各種食物 及飲料混合以及使其本身與料劑結合而使用於富 領域中。 刃 【圖式簡單說明】 I18664.doc 200800292 圖1顯示所回收灌注溶液中剩餘鈣含量之比率。使包含 鈣(1¾克/毫升)或包含終與GA(7.5%)之灌注溶液流過腸道 並在開始灌注後於10、20、3〇、40、5〇及6〇分鐘間隔時回 收500微升的各樣品。 圖2顯示3天總的鈣尿液排泄量。將包含鈣、G a或甸+ GA之水投與大鼠並分別以+Ca、+ga及+[Ca+GA]表示社 果。 圖3顯示餵食鈣及/或GA對大鼠體重增加之影響。,,對照·, 及”不含Ca”係指分別餵食正常飲食及缺鈣飲食之組之俨 重。 圖4顯示飯食鈣及/或GA對大鼠股骨硬度之影響。”對照” 及”不含Ca”與上文所述相同。 圖5顯示餵食鈣及/或Ga對大鼠股骨之Ca、Zn、人 量之影響。n對照"及"不含Ca,,與上文所述相同。 圖6顯示餵食鈣及/或GA對大鼠血液中alp之影響。”對 照M及"不含Can與上文所述相同。 118664.doc 14-
Claims (1)
- 200800292 申請專利範圍: ι· 2. 3. 4· 一種包括阿拉伯樹膠之鈣吸收加速劑。 匕括#5忒劑及如請求項1之加速劑之富鈣食物。 明求項1之加速劑在製造富飼食物中之用途。 -種包括阿拉伯樹膠與鈣試劑之組合物,其作為組之 劑用於在治療+同時、分開或依序使用。 、 5. 月求項4之組合物,其中該治療係預防或治療與缺約 有關之疾病。 月求項5之組合物,其中該疾病係骨質疏鬆症或骨 化。 7·-種:拉伯樹膠在製造用來治療或預防與缺約有關之疾 病之藥物中的用途。 8·如明求項7之用途,其中該藥物另外包括飼試劑。 化月求Μ 7或8之用途’其中該疾病係骨質疏鬆症或骨軟 1〇·丄種如請求項1之加速劑在製造用來治療或預防慢性腎 衣竭或與’1¾性腎衰竭有關之缺飼之藥物中的用途。 1 1 ·種如請求項1之加速劑在萝造用丈A、二波々、M 脈粥樣硬化、冠狀…預防包括動 ㈣脈疾病、局部缺血性心、臟病、高血 月曰症及高血壓在內夕 $ _ 隹内之〜血官疾病之藥物中的用途。 12 ·種如請求項1之加速劑在f芒用氺、Λ @斗、牧 旷i I仏用來治療或降低高膽固 -子血症患者中膽固醇之藥物中的用途。 13.二種如請求項1之加速劑在製造用來治療或預防癔疾之 藥物中的用途。 矢之 118664.doc 200800292 14 · ' 種如請求 、之加速劑在製造用來治療或^ 結腸炎之藥物中的用途。 … 1 5·、種如明求項1之加速劑在製造用來治療或預 或齒斑之藥物中的用途。、 1 6· 一種如請求項1之加速劑在製造用來治療或預 絲海默氏症或老年性癡呆症在内之學習缺陷之 用途。 17·如請求項1〇至16中任一項之用途,其中該藥物 #5試劑。 防潰殤性 防齒齦炎 防包括阿 藥物中的 另外包括118664.doc
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77437406P | 2006-02-17 | 2006-02-17 | |
JP2006041158 | 2006-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200800292A true TW200800292A (en) | 2008-01-01 |
Family
ID=38042502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096105942A TW200800292A (en) | 2006-02-17 | 2007-02-16 | Accelerating agent of calcium absorption |
Country Status (15)
Country | Link |
---|---|
US (2) | US20090098222A1 (zh) |
EP (2) | EP2298276B1 (zh) |
JP (1) | JP5281895B2 (zh) |
KR (1) | KR20080103528A (zh) |
CN (2) | CN101431959A (zh) |
AR (1) | AR059577A1 (zh) |
AT (1) | ATE535283T1 (zh) |
AU (1) | AU2007215753B2 (zh) |
BR (1) | BRPI0708061A2 (zh) |
CA (1) | CA2642248A1 (zh) |
MY (1) | MY147271A (zh) |
RU (1) | RU2428193C2 (zh) |
SG (1) | SG169979A1 (zh) |
TW (1) | TW200800292A (zh) |
WO (1) | WO2007094486A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007039310A1 (de) * | 2007-08-13 | 2009-02-19 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Zusammensetzung zur Prophylaxe und Behandlung von Osteoporose |
US9144249B2 (en) * | 2008-06-23 | 2015-09-29 | Amano Enzyme Usa, Ltd. | Enzymatic methods of flavor modification |
EP2836083B1 (en) | 2012-04-10 | 2016-08-03 | Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG | Wet granulation process and granulate material comprising arabic gum |
CN107929313B (zh) * | 2017-11-21 | 2021-02-19 | 上海金城素智药业有限公司 | 用于预防和治疗钙缺乏症的天然型牡蛎碳酸钙制剂及其制备方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4097601A (en) * | 1977-08-26 | 1978-06-27 | Pfizer Inc. | Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins |
US5545414A (en) * | 1995-03-22 | 1996-08-13 | Abbott Laboratories | Cholesterol lowering food product |
US5609897A (en) * | 1995-04-07 | 1997-03-11 | Abbott Laboratories | Powdered beverage concentrate or additive fortified with calcium and vitamin D |
JPH11503023A (ja) * | 1995-04-07 | 1999-03-23 | アボット・ラボラトリーズ | ビタミンdを含有するカルシウム補給剤およびカルシウム含有飲料 |
JP4493736B2 (ja) | 1995-09-01 | 2010-06-30 | 日本水産株式会社 | キチンを含有するミネラル吸収促進性組成物およびミネラル吸収促進用添加剤 |
US5855936A (en) * | 1997-03-21 | 1999-01-05 | Nestec S.A. | Food fortification |
JP3512113B2 (ja) * | 1997-03-24 | 2004-03-29 | 丸尾カルシウム株式会社 | 食品添加剤スラリー組成物及びパウダー組成物、並びにこれらを含有する食品組成物 |
JPH11313634A (ja) * | 1998-03-12 | 1999-11-16 | Internatl Flavors & Fragrances Inc <Iff> | 呈味剤とその製造方法 |
EP0960572A1 (en) * | 1998-05-12 | 1999-12-01 | N.V. Nutricia | Nutritional composition for the treatment of pressure ulcers |
JP2000026283A (ja) * | 1998-07-10 | 2000-01-25 | Nisshin Oil Mills Ltd:The | 油性組成物を含有した粉末組成物 |
US6455082B1 (en) * | 1999-04-26 | 2002-09-24 | Nestec S.A. | Shelf-stable calcium fortified milk and dairy products |
JP2001186863A (ja) * | 2000-01-05 | 2001-07-10 | Maruo Calcium Co Ltd | 食品添加剤スラリー組成物及びパウダー組成物、及びこれを含有する食品組成物 |
JP3563343B2 (ja) | 2000-11-10 | 2004-09-08 | 株式会社東洋新薬 | カルシウム利用効率が向上した食物繊維含有食品 |
JP2002223737A (ja) * | 2001-02-02 | 2002-08-13 | Dai Ichi Kogyo Seiyaku Co Ltd | カルシウム強化飲料用分散剤、及びカルシウム含有粉末 |
JP4390428B2 (ja) * | 2001-05-01 | 2009-12-24 | 株式会社林原生物化学研究所 | 含カルシウム組織強化剤 |
DE10127897B4 (de) * | 2001-06-08 | 2006-04-20 | Bionorica Ag | Manteltablette mit Pflanzentrockenextrakten |
US20030203097A1 (en) * | 2002-04-24 | 2003-10-30 | The Procter & Gamble Company | Acidic compositions comprising protein and fiber and processes of their preparation |
US7138151B2 (en) * | 2002-11-22 | 2006-11-21 | Unilab Pharmatech, Ltd. | Calcium-fortified acidic beverages |
JP2004292382A (ja) * | 2003-03-27 | 2004-10-21 | Kirin Brewery Co Ltd | ミネラル吸収促進剤及び骨粗鬆症用予防及び/又は改善剤 |
JP2005047820A (ja) * | 2003-07-29 | 2005-02-24 | Taiyo Kagaku Co Ltd | 整腸用組成物 |
KR20030078050A (ko) * | 2003-09-01 | 2003-10-04 | 주식회사 엠에스씨 | 고분산성 유청칼슘 조성물 및 그 제조방법 |
CN1833727B (zh) * | 2005-03-18 | 2010-07-28 | 潘思源 | 阿拉伯树胶在建立动物模型和降低血胆固醇中的用途 |
US20070003671A1 (en) * | 2005-07-01 | 2007-01-04 | Anglea Timothy A | Two-part calcium fortified compositions and methods of making the same |
CN101484146A (zh) * | 2006-05-23 | 2009-07-15 | 奥拉黑尔斯公司 | 木糖醇锭剂及其用法 |
-
2007
- 2007-02-13 KR KR1020087019993A patent/KR20080103528A/ko not_active Application Discontinuation
- 2007-02-13 US US12/223,969 patent/US20090098222A1/en not_active Abandoned
- 2007-02-13 JP JP2008539175A patent/JP5281895B2/ja active Active
- 2007-02-13 EP EP09011120.4A patent/EP2298276B1/en active Active
- 2007-02-13 BR BRPI0708061-1A patent/BRPI0708061A2/pt not_active IP Right Cessation
- 2007-02-13 AU AU2007215753A patent/AU2007215753B2/en not_active Ceased
- 2007-02-13 AT AT07714433T patent/ATE535283T1/de active
- 2007-02-13 CN CNA200780013329XA patent/CN101431959A/zh active Pending
- 2007-02-13 AR ARP070100597A patent/AR059577A1/es unknown
- 2007-02-13 CA CA002642248A patent/CA2642248A1/en not_active Abandoned
- 2007-02-13 WO PCT/JP2007/052906 patent/WO2007094486A1/en active Search and Examination
- 2007-02-13 EP EP07714433A patent/EP1986566B1/en active Active
- 2007-02-13 RU RU2008137129/15A patent/RU2428193C2/ru not_active IP Right Cessation
- 2007-02-13 CN CN2012102187846A patent/CN102755374A/zh active Pending
- 2007-02-13 SG SG201101052-7A patent/SG169979A1/en unknown
- 2007-02-16 TW TW096105942A patent/TW200800292A/zh unknown
-
2008
- 2008-08-13 MY MYPI20083071A patent/MY147271A/en unknown
-
2010
- 2010-08-27 US US12/870,318 patent/US20110045014A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20080103528A (ko) | 2008-11-27 |
MY147271A (en) | 2012-11-30 |
BRPI0708061A2 (pt) | 2011-05-17 |
EP2298276B1 (en) | 2020-01-15 |
AR059577A1 (es) | 2008-04-16 |
AU2007215753A1 (en) | 2007-08-23 |
EP2298276A1 (en) | 2011-03-23 |
US20090098222A1 (en) | 2009-04-16 |
US20110045014A1 (en) | 2011-02-24 |
EP1986566A1 (en) | 2008-11-05 |
WO2007094486A1 (en) | 2007-08-23 |
AU2007215753B2 (en) | 2013-04-18 |
JP5281895B2 (ja) | 2013-09-04 |
SG169979A1 (en) | 2011-04-29 |
ATE535283T1 (de) | 2011-12-15 |
JP2009526748A (ja) | 2009-07-23 |
CN102755374A (zh) | 2012-10-31 |
RU2008137129A (ru) | 2010-03-27 |
CA2642248A1 (en) | 2007-08-23 |
RU2428193C2 (ru) | 2011-09-10 |
EP1986566B1 (en) | 2011-11-30 |
CN101431959A (zh) | 2009-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2648653C (en) | Fat accumulation inhibitor | |
TW200848064A (en) | Process for producing osteocalcin-containing extract | |
JPH09191852A (ja) | 健康食品 | |
JPH07278012A (ja) | 新陳代謝促進剤およびそれを配合した食品 | |
WO2011094458A1 (en) | Agmatine containing dietary supplements, nutraceuticals and foods | |
EP2127663A1 (en) | Adiponectin production enhancer | |
JP3393560B2 (ja) | 水溶性キトサンを含有するカルシウム吸収促進性組成物およびカルシウム吸収促進用添加剤 | |
TW200800292A (en) | Accelerating agent of calcium absorption | |
JP2007022989A (ja) | 抗疲労剤 | |
JP2003155244A (ja) | モズク由来のフコイダンを含む食品 | |
JP3459932B2 (ja) | 抗骨粗鬆症組成物 | |
JP3433917B2 (ja) | 体タンパク質蓄積効率を亢進する栄養組成物 | |
JP4914594B2 (ja) | 関節痛改善用食品組成物 | |
JPH0549444A (ja) | 耐久力増強用食品 | |
RU2274003C2 (ru) | Способ комплексной переработки крови сельскохозяйственных животных для получения биологически активного вещества с противоанемическими свойствами на основе гемоглобина, биологически активное вещество с противоанемическими свойствами (варианты) и продукт, его содержащий (варианты). | |
TWI530256B (zh) | 以鐵結合型乳鐵蛋白製備抗精神疲勞劑之方法 | |
WO2015190682A1 (ko) | 쿠마린산을 유효성분으로 포함하는 성장 촉진용 조성물 | |
KR101629517B1 (ko) | 경구 조성물 | |
EP1170013A1 (en) | Drugs, foods, drinks and feeds containing cocoa component | |
ES2781428T3 (es) | Agente acelerador de absorción de calcio | |
JPH11243914A (ja) | カルシウム吸収促進飲食物 | |
JP2010095474A (ja) | カルシウム吸収促進組成物及びカルシウム吸収促進飲食物 | |
JP3556757B2 (ja) | 吸収促進性糖類組成物 | |
JP2009533433A (ja) | ピルビン酸アルキルエステルを含む組成物とその使用 | |
JPH07100022B2 (ja) | 健康食品 |